Compare · INMD vs NRXS
INMD vs NRXS
Side-by-side comparison of InMode Ltd. (INMD) and Neuraxis Inc. (NRXS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INMD and NRXS operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- INMD is the larger of the two at $730.0M, about 11.4x NRXS ($63.9M).
- NRXS has been more active in the news (5 items in the past 4 weeks vs 3 for INMD).
- INMD has more recent analyst coverage (20 ratings vs 0 for NRXS).
- Company
- InMode Ltd.
- Neuraxis Inc.
- Price
- -
- -
- Market cap
- $730.0M
- $63.9M
- 1M return
- -9.48%
- -
- 1Y return
- -7.60%
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- AMEX
- IPO
- 2019
- 2023
- News (4w)
- 3
- 5
- Recent ratings
- 20
- 0
InMode Ltd.
InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies. The company offers minimally-invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. InMode Ltd. offers its products directly in United States, Canada, United Kingdom, Spain, India, Australia, and France, as well as through distributors in 47 countries. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.
Latest INMD
- SEC Form 6-K filed by InMode Ltd.
- InMode Reports Third Quarter 2026 Financial Results: Quarterly GAAP Revenues of $92.1 Million; Reaffirms Full-Year 2026 Financial Outlook
- SEC Form 6-K filed by InMode Ltd.
- Steel Partners Holdings L.P. Issues Open Letter to All InMode Stakeholders and Sets October 30, 2026 Expiration for Its $16.75 Per Share All-Cash Offer
- InMode to Report Third Quarter 2026 Financial Results on November 11, 2026, Expects Third Quarter Revenue of $91.8 Million to $92.0 Million, Reiterates FY 2026 Revenue Guidance Between $365M-$375M
- SEC Form 6-K filed by InMode Ltd.
- InMode Advances RF Microneedling Comfort with the Launch of Morpheus8 Cool
- SEC Form 6-K filed by InMode Ltd.
- Chief Financial Officer Itzkovich Moshe was granted 14,000 units of Ordinary Shares, increasing direct ownership by 57% to 38,430 units (SEC Form 4)
- SEC Form 6-K filed by InMode Ltd.
Latest NRXS
- Amendment: SEC Form SCHEDULE 13D/A filed by Neuraxis Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Neuraxis Inc.
- NeurAxis Reports Record Third Quarter 2026 Financial Results Driven by 150% Year Over Year Revenue Growth
- SEC Form 10-Q filed by Neuraxis Inc.
- NeurAxis to Host Third Quarter 2026 Results and Business Update Call on Monday, November 9, 2026
- NeurAxis Announces Medical Policy Coverage Milestone, Expanding Access to 26 Million Additional Covered Lives
- SEC Form 8-K filed by Neuraxis Inc.
- Chief Executive Officer Carrico Brian Allen bought $1,297 worth of shares (268 units at $4.84) (SEC Form 4)
- CRO, CCO, CPO Carrico Thomas Joeseph bought $1,588 worth of shares (328 units at $4.84) (SEC Form 4)
- Chief Financial Officer Henrichs Timothy Robert bought $9,375 worth of shares (1,937 units at $4.84) (SEC Form 4)